Yttrium‐86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole‐Body Distribution of Gadolinium‐Based Contrast Agents

Gadolinium‐based contrast agents (GBCAs) are used to provide diagnostic information in clinical magnetic resonance (MR) examinations. Gadolinium (Gd) has been detected in the brain, bone and skin of patients, months and years following GBCA administration, raising concerns about long term toxicity....

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2020-01, Vol.59 (4), p.1474-1478
Main Authors: Le Fur, Mariane, Rotile, Nicholas J., Correcher, Carlos, Clavijo Jordan, Veronica, Ross, Alana W., Catana, Ciprian, Caravan, Peter
Format: Article
Language:English
Subjects:
Biocompatibility
Contrast agents
Contrast Media
Diagnostic systems
Gadolinium
Gadolinium - chemistry
gadolinium retention
Humans
imaging agents
Isotopes
Magnetic resonance
magnetic resonance imaging
Magnetic Resonance Imaging - methods
Neuroimaging
Organic chemistry
Positron emission tomography
Toxicity
Yttrium
Yttrium Radioisotopes - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gadolinium‐based contrast agents (GBCAs) are used to provide diagnostic information in clinical magnetic resonance (MR) examinations. Gadolinium (Gd) has been detected in the brain, bone and skin of patients, months and years following GBCA administration, raising concerns about long term toxicity. Despite increased scrutiny, the concentration, chemical form and fate of the retained gadolinium species remain unknown. Importantly, the whole body biodistribution and organ clearance of GBCAs is poorly understood in humans. Gadolinium lacks suitable isotopes for nuclear imaging. We demonstrate that the yttrium‐86 isotope can be used as a gadolinium surrogate. We show that Gd and their analogous Y complexes have similar properties both in solution and in vivo, and that yttrium‐86 PET can be used to track the biodistribution of GBCAs over a two‐day period. Yttrium‐86 PET imaging can inform on the clearance and biodistribution of the gadolinium‐based contrast agents used in MRI. Trace amounts of contrast agent can be detected in kidney 48 h post injection in rodents.
ISSN:1433-7851
1521-3773
DOI:10.1002/anie.201911858